Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast

Rhea-AI Summary

Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced it will disclose its third-quarter 2022 financial and operational results before the market opens on November 8, 2022. Following the results, a live conference call and webcast will occur at 8:30 a.m. ET to discuss the findings. Interested participants can register for the call to receive dial-in details and access a live webcast on Voyager's investor website. Voyager is focused on next-generation AAV gene therapy, aiming to treat debilitating diseases using its proprietary capsids from the TRACER™ discovery platform.

Positive

• Focus on next-generation AAV gene therapy, indicating potential for innovative treatments.
• Proprietary TRACER™ capsid discovery platform may enhance the effectiveness of therapies.

Negative

• None.

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced it will report third quarter 2022 financial and operating results before the market opens on Tuesday, November 8, 2022. Subsequently, the Company will host a live conference call and webcast at 8:30 a.m. ET to review its financial and operating results.

To participate via telephone and join the call live, please register in advance here: https://register.vevent.com/register/BIa813418ea1c148dda525a8560a51e1ca. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode. A live webcast of the call will also be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from Voyager’s TRACER™ capsid discovery platform are powering a rich early-stage pipeline of programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas.
voyagertherapeutics.com        LinkedIn        Twitter 

Voyager Therapeutics^® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. 

FAQ

When will Voyager Therapeutics report its Q3 2022 results?

Voyager Therapeutics will report its Q3 2022 financial and operating results on November 8, 2022.

What time is the Voyager Therapeutics conference call for Q3 results?

The conference call for Voyager's Q3 results will take place at 8:30 a.m. ET on November 8, 2022.

How can I participate in the Voyager Therapeutics conference call?

You can register in advance for the Voyager Therapeutics conference call through their investor website to receive details on how to join.

What is the focus of Voyager Therapeutics?

Voyager Therapeutics is focused on next-generation AAV gene therapy to treat debilitating diseases.